Wyniki wyszukiwania:

At the turn of the twentieth century, New York s Bowery District becomes the scene of a terrible murder when the Klezmer King gets fried to a crisp by his Electric Tuxedo on stage The Inquisitor s apprentice, thirteen-year-old Sacha Kessler, tries to help find the killer, but the closer he gets to solving the crime, the more it sounds as if the creature that haunted him in his first adventure is back. Worse still, his own family is in danger. Sacha has avoided learning magic until now, but as his world falls apart around him, he changes his mind."

The day Sacha found out he could see witches was the worst day of his life . . .

Being an Inquisitor is no job for a nice Jewish boy. But when the police learn that Sacha Kessler can see witches, he's apprenticed to the department's star Inquisitor, Maximillian Wolf. Their mission is to stop magical crime. And New York at the beginning of the twentieth century is a magical melting pot where each ethnic group has its own brand of homegrown witchcraft, and magical gangs rule the streets from Hell's Kitchen to Chinatown.

Soon Sacha has teamed up with fellow apprentice Lily...

Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac...

Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac...